GGHC
ABCL icon

Gilder Gagnon Howe & Co’s AbCellera Biologics ABCL Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-454,598
Closed -$18.3M – 392
2020
Q4 		$18.3M Buy
+454,598
New +$20.8M 0.09% 152

Other funds holding ABCL

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Gilder Gagnon Howe & Co's ABCL Position: Q1 2021 in Review

Gilder Gagnon Howe & Co sold out of AbCellera Biologics (ABCL) in Q1 2021, closing a stake of 454,598 shares — an estimated $18.3M sold.

Gilder Gagnon Howe & Co first reported a position in ABCL in Q4 2020 and held it in 1 quarter. The position peaked at $18.3M in Q4 2020. 86 funds tracked by Wall St. Rank hold ABCL as of Q1 2021.

  • Gilder Gagnon Howe & Co reported no remaining AbCellera Biologics position as of Q1 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 454,598 AbCellera Biologics shares in Q1 2021, an estimated $18.3M.
  • Gilder Gagnon Howe & Co first reported a position in AbCellera Biologics in Q4 2020 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's AbCellera Biologics position peaked at $18.3M in Q4 2020.
  • 86 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2021, filed 17 May 2021.